Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 23;13(12):e15332.
doi: 10.5812/hepatmon.15332. eCollection 2013.

Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment

Affiliations

Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment

Xue-Ping Yu et al. Hepat Mon. .

Abstract

Background: The restoration of HBV-specific T-cell response during antiviral therapy is associated with CD4+T-cell activity. Treg cells and Th17 cells are subtypes of CD4+T cell. However, it has remained unknown how the Treg and Th17 cells and their associated cytokines affect nucleos(t)ide analogues (NA) antiviral efficacy.

Objectives: The aim of the present study was to provide a new insight to evaluate the NA antiviral therapy for patients with chronic hepatitis B (CHB).

Patients and methods: Forty-four CHB patients hospitalized between July 2010 and August 2011 were enrolled in this study. They were received NA (entecavir, lamivudine and adefovir) treatment for 14.42 ± 13.08 weeks, and the peripheral blood was collected. The frequencies of Treg and Th17 cells were detected by flow cytometric analysis, and the levels of IL-10, TGF-β1, IL-17 and IL-23 were measured by enzyme-linked immunosorbent assay (ELISA).

Results: In complete and partial-responders, Treg cells frequencies and IL-10, TGF-β1, IL-23 levels were all decreased significantly after NA therapy, while Th17 cells and the IL-17 levels were increased slightly. Treg/Th17 ratio was only dramatically declined in complete-responders. But there was no significant difference in non-responders. Either HBV DNA decreased by at least 2 log copies /mL or ALT turned to normal level, Treg cells frequencies and IL-10, TGF-β1, IL-23 levels were significantly reduced. Meanwhile, Treg cells were positively correlated with HBV DNA and ALT.

Conclusions: The changes of Treg and Th17 cells and their associated cytokines were related to virological and biochemical responses.

Keywords: Cytokines; Hepatitis B, Chronic; T-Lymphocytes, Regulatory; Th17 Cells.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The Changes of Treg and Th17 Cells in Different Responders CHB Patients Before and After Nucleos(t)ide Analogues Antivirus Therapy
A representative CD127 low expression in CD4 + CD25 high T subsets from each response group was shown. B representative IL-17A expression in CD3 + CD8 T subsets (CD4 + subsets) form each response group was shown. The mean percentage of positive cells was shown in each panel.
Figure 2.
Figure 2.. The Correlation Between Treg Cells Frequencies, HBV DNA Loads, and ALT Levels
The Spearman's rank correlation was performed between the variables. The frequencies of Treg cells were positively correlated with HBV DNA load (A) and ALT levels (B). And the HBV DNA load was positively correlated with ALT levels (C).

Similar articles

Cited by

References

    1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28(1):112–125. - PubMed
    1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158–68. - PubMed
    1. Chisari FV. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol. 2000;156(4):1117. - PMC - PubMed
    1. Juszczyk J, Boron-Kaczmarska A, Cianciara J, Flisiak R, Gladysz A, Halota W, et al. [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations]. Pol Merkur Lekarski. 2010;29(170):103–6. - PubMed
    1. Dienstag JL. Hepatitis B virus infection. New Eng J Med. 2008;359(14):1486–1500. - PubMed

LinkOut - more resources